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Abstract
Background: Poor-quality life-saving medicines are a major public health threat, particularly in settings with a weak
regulatory environment. Insufficient amounts of active pharmaceutical ingredients (API) endanger patient safety and may
contribute to the development of drug resistance. In the case of malaria, concerns relate to implications for the efficacy of
artemisinin-based combination therapies (ACT). In Papua New Guinea (PNG), Plasmodium falciparum and P. vivax are both
endemic and health facilities are the main source of treatment. ACT has been introduced as first-line treatment but other
drugs, such as primaquine for the treatment of P. vivax hypnozoites, are widely available. This study investigated the quality
of antimalarial drugs and selected antibiotics at all levels of the health facility supply chain in PNG.
Methods and Findings: Medicines were obtained from randomly sampled health facilities and selected warehouses and
hospitals across PNG and analysed for API content using validated high performance liquid chromatography (HPLC). Of 360
tablet/capsule samples from 60 providers, 9.7% (95% CI 6.9, 13.3) contained less, and 0.6% more, API than pharmacopoeial
reference ranges, including 29/37 (78.4%) primaquine, 3/70 (4.3%) amodiaquine, and one sample each of quinine,
artemether, sulphadoxine-pyrimethamine and amoxicillin. According to the package label, 86.5% of poor-quality samples
originated from India. Poor-quality medicines were found in 48.3% of providers at all levels of the supply chain. Drug quality
was unrelated to storage conditions.
Conclusions: This study documents the presence of poor-quality medicines, particularly primaquine, throughout PNG.
Primaquine is the only available transmission-blocking antimalarial, likely to become important to prevent the spread of
artemisinin-resistant P. falciparum and eliminating P. vivax hypnozoites. The availability of poor-quality medicines reflects
the lack of adequate quality control and regulatory mechanisms. Measures to stop the availability of poor-quality medicines
should include limiting procurement to WHO prequalified products and implementing routine quality testing.
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Introduction
Prompt and effective treatment of clinical episodes of malaria is
one of the central pillars of malaria control programs [1]. It is
critical for preventing progression to severe disease or death and
reducing the reservoir of Plasmodium parasites in the population.
The World Health Organization’s (WHO) ‘‘T3: Test. Treat.
Track.’’ initiative emphasises that every confirmed case of malaria
should be treated with an antimalarial medicine that is quality-
assured and efficacious in the specific local setting [2].
The quality of antimalarial medicines has come under scrutiny
after an increasing number of reports identified poor-quality
products in malaria-endemic countries in Africa, Asia and Latin
America [3–6]. A recently published review found that 35% of
antimalarial drug samples from seven countries in southeast Asia
and 21 countries in sub-Saharan Africa had failed chemical
content analysis [3]. A number of studies found products sampled
from unlicensed providers to be of poor quality more frequently
than products from licensed providers (pharmacies, health
facilities) [7]. While antimalarial drug quality has been studied
more extensively, the problem extends to other anti-infective
drugs, particularly antibiotics and anti-retrovirals, and beyond [7–
9]. Estimates of the prevalence of poor-quality medicines vary
widely as a result of a lack of surveillance and testing capacity, and
disagreements between stakeholders on definitions and appropri-
ate action [10,11]. Resource-poor countries, in which regulatory
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and law enforcement systems are insufficient for detecting poor-
quality products and preventing them from entering or remaining
on the local medicines market, are likely to be most affected
[12,13]. The discovery of 1.4 million packets of fake Coartem
(artemether-lumefantrine) hidden in loudspeaker boxes in a
shipping container in Luanda (Angola) in 2012 may be an
indication of the magnitude of the problem and of the criminal
energy driving it [14].
Poor-quality life-saving medicines endanger patient safety and
are recognised as a major public health threat [11,13,15,16]. Poor-
quality products can result from sub-standard manufacturing
practices, or they may degrade due to inadequate transportation
and storage conditions. The end result is products with less than
the required amount of active pharmaceutical ingredient (API)
[17]. Falsified medicines, on the other hand, are due to deliberate
fraudulent activity and often contain only traces of or no relevant
active ingredient at all. The term ‘counterfeit medicines’ is in this
context generally used when referring to intellectual property
rights infringements [17,18].
The exposure of malaria parasites to sub-lethal amounts of
antimalarial medicines may result in treatment failure and
ultimately death of a patient but may also contribute to the
development of drug resistance [19]. Particular concerns relate to
the emergence of falsified artemisinin derivatives and potential
implications for the efficacy of artemisinin-based combination
therapies (ACT) [3]. In Papua New Guinea (PNG), where
Plasmodium falciparum and P. vivax are both endemic [20], the
National Department of Health has recently introduced ACT as
first-line treatment [21]. However, other antimalarial medicines,
such as primaquine for the treatment of P. vivax hypnozoites, are
widely available [22].
Medicines can be obtained from a variety of sources but the
over 4,000 formal health facilities (government, church and
privately run hospitals, health centres and aid posts) represent the
widest network of providers [23]. Two studies conducted primarily
in rural settings of PNG reported that health facilities were the
most common source of antimalarial treatment [24–26]. A
national household survey carried out in 2008/09 found that
45% of recently febrile household members had attended a health
facility and 74% of them had received an antimalarial medicine.
Of the 55% not attending a health facility only 9% reported taking
an antimalarial [25]. The situation of other anti-infective drugs,
particularly common antibiotics, has not been thoroughly inves-
tigated. Malaria treatment can also be obtained from private
licensed pharmacies, of which there were 76 in 2011, according to
the PNG Pharmacy Board [27]. In certain places, street vendors,
markets and retail stores may represent additional sources of
medicines, but to the authors’ knowledge, the local market
structure for medicines has never been thoroughly investigated.
While dispensing of pharmaceuticals is limited to licensed
providers, there are numerous gaps in the regulatory framework
and its enforcement [27].
The supply of medicines to government and church-run health
facilities follows a push-system centralised at the National
Department of Health. Distribution to facilities relies on a network
of regional warehouses (area medical stores, AMS) and provincial
transit stores [27]. Delivery from provincial stores to individual
facilities is the responsibility of provincial health offices/authori-
ties. Individual disease control programs may circumvent the
routine delivery procedures and church-run facilities may also
obtain medicines through their own supply channels.
In the absence of routine quality control procedures [27], little is
known about the quality of medicines dispensed in PNG. Only
recently has the Global Fund Round 8 malaria grant [28]
provided funding for establishing a Minilab (Global Pharma
Health Fund e.V., Germany) testing facility at the Central Public
Health Laboratory (CPHL). In 2011, a first small-scale study
found substandard and counterfeit anti-infective medicines in
private pharmacies in Port Moresby [29]. While these results are
alarming, the evidence base is very limited and the data not
representative for the country as a whole. The quality of medicines
at the level of providers in rural areas may differ substantially from
the quality found in the capital [30]. Similarly, medicines found on
offer at different types of providers may be of different quality as
the sources and storage conditions for drugs may vary.
This study aimed to investigate the quality of antimalarial
medicines at all levels of the health facility drug supply chain in
PNG in order to provide an understanding of the exposure of
malaria patients to poor-quality products. At the time of the study,
the new treatment protocol introducing artemether-lumefantrine
(AL) as first-line treatment for uncomplicated P. falciparum malaria,
and AL plus primaquine as first-line treatment for uncomplicated
P. vivax malaria was in the early stages of implementation and AL
had not yet been distributed to all health facilities. The study was
extended to sampling two antibiotics as examples of anti-infective
medicines frequently used for the treatment of non-malarial fevers.
Where possible, this report follows the Medicine Quality
Assessment Reporting Guidelines (MEDQUARG) [17].
Methods
Ethical Statement
The study protocol was reviewed and granted ethical clearance
by the PNG Institute of Medical Research Institutional Review
Board (IMR IRB No. 1115) and the PNG Medical Research
Advisory Committee (MRAC No. 11.25). Verbal approval to
collect medicine samples was obtained from the officers-in-charge
of the respective providers.
Product Sampling
Samples of medicines were collected in 2011 during a national
cross-sectional health facility survey which included randomly
sampled health centres, health sub-centres (here collectively
referred to as health centres) and aid posts. Two health centres
and up to four aid posts were randomly sampled from each of 20
provinces of PNG, using a simple random sampling procedure.
The sampling frame was a list of all 689 operational public-sector
health centres as provided by the National Department of Health.
Aid posts were randomly selected from a list of all operational aid
posts under the supervision of the health centre at the time of
survey. The health facility survey was the second in a series carried
out for the evaluation of the National Malaria Control Program
and the survey methodology is described in more detail elsewhere
[31].
Trained field interviewers from the Papua New Guinea Institute
of Medical Research (PNG IMR) collected samples of a minimum
of 30 tablets or capsules of medicines available in the facility,
including separate samples of the same drug if the brand/
manufacturer or dosage strength differed. The range of products
included oral tablet/capsule formulations of all antimalarial
medicines used in the previous and current malaria treatment
guidelines [21,32,33] as well as amoxicillin and doxycycline (which
is also used in treating malaria [34]). Samples were collected after
full disclosure of the study objectives to the officer-in-charge of the
respective facility. When required, field interviewers provided
replacement medicines obtained from the AMS in the town of
Lae. In addition to the health centres and aid posts, medicines
were collected from a convenience sample of provincial hospitals
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and AMS following the same collection approach as described
above.
Medicines were collected in their original blisters or jars, or, in
case of large containers (e.g. containing 1,000 tablets), sampled
into a plastic zip-lock bag. Each sample was labelled with a unique
identifier. Details of each drug sample, such as API, dosage
strength, manufacturer’s details, etc. were copied from the package
into a data collection form. For each provider, basic information
about their drug storage facility was recorded. Drug samples were
stored dark in an air-conditioned room at the CPHL before being
sent to Australia for chemical content analysis.
Product Evaluation
Medicine samples were analysed for API content at Curtin
University School of Pharmacy in Perth, Australia, using a high
performance liquid chromatography (HPLC; Hewlett Packard
model 1100) system comprised of a gradient pump, autosampler
and a variable wavelength UV detector (Agilent Technology,
Waldbronn, Germany). A five point calibration curve was
generated for each drug. Each calibration curve demonstrated to
be linear showing a regression coefficient r2$0.999. Chromato-
gram analysis was performed using Chemstation Software
(Version 9, Agilent Technology). Published HPLC methods were
modified as required for each drug analysis (Table 1). Chemistry
analyses were performed blinded to packaging of the medicines.
Sample preparation and analysis techniques. Standards
and samples of each drug were prepared using the diluents listed in
Table 2. The reference drugs were obtained from Sigma-Aldrich,
Castle Hill, Australia (amoxicillin, artesunate, chloroquine diphos-
phate, doxycycline, primaquine diphosphate, sulphadoxine &
pyrimethamine), Sigma Chemicals, Perth, Western Australia
(quinine hydrochloride), Sigma Chemicals, St Louis, MO, USA
(amodiaquine dihydrochloride dihydrate), AAPIN Chemicals Ltd
Abingdon, UK (artemether) and Shaani Sciphar, Biotechnology,
Chime Co. Ltd., China (lumefantrine). Standard concentrations
were prepared at 1 mg/mL. All stock solutions were stored at 4uC.
Chloroquine and amodiaquine were analysed for individual tablet
content. Six individual tablets from each batch were weighed,
dissolved and analysed individually. For the other drugs, 3–20
tablets from each batch were weighed to obtain the average tablet
weight (Table 2). The tablets were then crushed to fine powder.
Each sample was prepared by dissolving the amount of powder
equivalent to the average weight of one tablet. The solutions were
sonicated for 10 min 6 2 and then equilibrated to room
temperature for 30 minutes. A known volume of the clear solution
of the first dilution was assayed or further dilutions were done if
required to remain within the assay limit (Table 2).
Chemical content analysis of primaquine tablets by LC-
MS. Primaquine tablet samples were also tested by liquid
chromatography-mass spectrometry (LC-MS) for quality control
purposes. The LC-MS and chromatographic conditions were
consistent with previously published methods [35]. The single-
quad LC-MS system (model 2020, Shimadzu, Kyoto, Japan) was
used for the analysis. Separation was performed in isocratic mode
using a Luna C18 (100 mm 6 4.6 mm i.d., 3 mm) column,
(Phenomenex, Lane Cove, Australia). Mobile phase consisting of
methanol:water (80:20 v/v) with 0.1% formic acid was pumped
with a flow rate of 0.25 ml/min. Primaquine and 8-aminoquino-
line was scanned first in ESI positive mode to identify the
abundance of ions. Quantitation was performed by selected ion
monitoring in ESI positive mode using protonated parent
molecule [M=H]+; m/z 260 for primaquine and protonated
parent molecule [M=H]+; m/z 145 for 8-aminoquinoline. A five
point calibration from 1–7 mg/ml was constructed in 0.1% formic
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acid and each standard and batch sample was spiked with 0.5 mg
of 8 aminoquinoline (IS). The standard curve was linear with
r2 = 0.99. Each batch of tablets was injected in random order
along with the quality control samples. Data was processed using
LAB Solution (Version 5, Shimadzu, Japan).
Data Analysis
Questionnaire data were double-entered into a DMSys
database (version 5.1, Sigma Soft International) at PNG Institute
of Medical Research and linked to HPLC assay results in Stata
(version 12.1, StataCorp) which was also used for data analysis.
A sample was considered to have failed chemical content
analysis if the measured percentage of API was below or above the
acceptable range defined in the British, International, or US
Pharmacopoeia (reference values provided in Table 3). Differences
in primaquine content detected by LC-MS and HPLC were #
8.3% but minor differences in samples near the lower reference
threshold (93%) resulted in fewer samples failing the LC-MS assay.
In the results, the LC-MS data are presented but comparative data
of both methods are provided as Table S1. Content of active
ingredient of a samples (mg/ml) was calculated from standard
curve6dilution (25*100)6 (average tablet weight/assay weight)/
1000= total drug in each sample (mg).
Univariate analysis was performed to describe basic character-
istics of the samples. The outcomes of the chemical content
analyses (pass/fail) were compared across regions, type of
provider, and other co-variates. Bivariate analyses included
Fisher’s exact and chi-square tests. Multilevel models with random
effect were fitted to assess associations of individual sample content
analysis outcome and country of origin, provider type and storage
conditions taking into consideration possible clustering at a
provider-level. Multivariable logistic regression was used to assess
the association of storage conditions and facility-level availability
of poor-quality drugs.
Results
Sources and Types of Samples
The survey covered 60 providers, including 12 hospitals, 17
health centres, 22 aid posts, 4 urban clinics (collectively referred to
as health facilities) and 5 AMS. Providers were located in 18/20
provinces. Delays in the ethical approval process prevented the
collection of samples in the first provinces covered by the health
facility survey (New Ireland, West New Britain).
A total of 392 medicine samples in the form of tablets or
capsules were collected, 385 of which were available in sufficient
quantity to be analysed for API content by HPLC/LC-MS. Of
these, 6 (one amodiaquine, one chloroquine, four primaquine) had
expired before 2011, the year of collection, 16 (one SP, one
chloroquine, four quinine, four primaquine, two artesunate, four
doxycycline) had expired between collection and the time of
performing the chemical content analysis in 2012, and for two
samples (one primaquine, one artemether), no expiry date was
available. These samples were analysed separately and results
presented as supplementary information (Tables S1 and S2). A
single sample of quinidine was excluded from analysis.
Content of Active Pharmaceutical Ingredient
Of 360 unexpired samples, 37 (10.3%; 95% confidence interval
[CI] 7.3, 13.9) failed the chemical content analysis. Two failed
samples of quinine (0.6% of all samples, 95% CI 0.1, 2.2)
contained more than the acceptable amount of API while 35
samples (9.7%; 95% CI 6.9, 13.3) contained less API than
acceptable (as defined in Table 3). In all of the tested samples some
active ingredient was detected. Failed samples included 29 (78.4%)
primaquine, 3 (4.3%) amodiaquine, 2 (6.3%) quinine, 1 (4.5%)
artemether, 1 (1.8%) SP and 1 (4.3%) amoxicillin capsule sample
(Table 4). The failed primaquine samples contained on average
70.7% (standard deviation [SD] 10.9) of API, the failed
amodiaquine samples 45.2% (SD 5.4). The two failed quinine
samples contained 106.5% and 105.2% API. Details of all failed
samples are presented as Table S2.
Labelled Origin of Samples
The majority of the medicines was collected in packages that
were un-opened or sealed (where applicable) at the time of
collection (83.1% of collected samples, 81.1% of failed samples).
According to the package labels, most of the 360 analysed samples
were manufactured in China (57.2%) and India (40.8%) (Table 5).
The remaining samples originated from Indonesia (5) and
Switzerland (1). The origin of one sample could not be ascertained
on the basis of the manufacturer name recorded by the field data
collector. Most of the 37 samples that failed the chemical content
analysis had been manufactured in India (86.5%; 95% CI 71.2,
95.5) according to the package label (Table 5). The remaining
failed samples originated from China (4) and Indonesia (1). In
total, 21.8% (32/147) of the samples from India and 1.9% (4/206)
Table 2. Standard and sample preparations for HPLC assay.
Drug Tablet strength (mg) Tablets per batch Diluent 1st dilution (ml) 2nd dilution factor
Amodiaquine 100 6 Water 100 2
Amoxicillin capsules 500 20 0.1% H3PO4 100 10
Amoxicillin tablets 250 20 0.1% H3PO4 100 5
Artemether 50 6–20 Acetonitrile 100 –
Artemether-lumefantrine 20/120 3–20 Acetonitrile +2% acetic acid 100 2
Artesunate 50 6–20 Acetonitrile 100 –
Chloroquine 150 6 Water 100 3
Doxycycline hyclate 100 20 0.01M HCL 100 5
Primaquine phosphate 7.5/13.2/26.3 20 Water +0.1% formic acid 100 –
Quinine sulphate 300 20 Methanol 100 5
Sulphadoxin-pyrimethamine 500/25 20 Acetonitrile 200 5
doi:10.1371/journal.pone.0096810.t002
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of the samples from China failed the chemical content analysis.
The difference between samples from India and China was partly
explained by the large proportion of primaquine samples that were
labelled as originating from India (89.2%). After adjusting for
primaquine, the difference between samples from India and China
remained statistically significance but with a wide confidence
interval (adjusted odds ratio [AOR]= 4.4, 95% CI 1.0, 19.6,
p = 0.048).
The 360 samples originated from a total of thirteen manufac-
turers, according to the package labels. Only two manufacturers’
products (artemether-lumefantrine from Ipca, India and Novartis,
Switzerland) were WHO prequalified [36] and both passed the
content analysis. The 37 failed samples were manufactured by
nine different companies. In the case of three manufacturers, all
collected samples failed the chemical content analysis (Table 6).
The degree to which the measured API content deviated from the
acceptable range differed between the manufacturers. Products
with particularly low levels of API originated from three
companies (Bharat Parenterals, Dev Life Corporation and Trends
Pharma) (Table S2).
The authors contacted the manufacturers of unexpired failed
samples in order to verify the authenticity of the package and with
it the origin of the product. Manufacturers producing only one or
two failed samples were not contacted. Representatives of four
manufacturers (BDH Industries, Bharat Parenterals, Dev Life
Corporation and Trends Pharma) confirmed the authenticity of
the packages. Sample photographs of packages are provided as
supplementary information (Figure S1).
Poor-quality Products in the Health Facility Supply Chain
Medicines that failed content analysis were found at all levels of
the supply chain, with the largest number collected from hospitals
and health centres (Table 7). The proportion of failed samples was
highest in area medical stores (5/22, 22.7%) and hospitals (14/88,
15.9%), and lower in health centres (10/120, 8.3%), urban clinics
(3/30, 10.0%) and aid posts (5/100, 5.0%). Differences between
providers were largely explained by the number of primaquine
samples collected and were not statistically significant in a
multilevel analysis after adjusting for primaquine (p.0.1 for all
provider types).
Failed medicines were found in 16/18 surveyed provinces
(except Western Province and Bougainville) and in 48.3% of the
60 providers sampled for this study, including all five area medical
stores, 8/12 (66.7%; 95% CI 34.9, 90.1) hospitals, 8/17 (47.1%;
95% CI 23.0, 72.2) health centres, 5/22 (22.7%; 95% CI 7.8, 45.4)
aid posts and 3/4 (75%; 95% CI 19.4, 99.4) urban clinics. The
difference between types of providers was not statistically
significant after correcting for primaquine in a multivariate logistic
regression (all p.0.9). The facility-level analysis confirmed that the
presence of poor-quality medicines was not correlated with the
presence of a separate storage room (43/60; AOR=0.94, 95%CI
0.18, 4.96, p = 0.95) or an air conditioning system for the storage
room (17/60; AOR=2.99, 95% CI 0.50, 17.69, p = 0.23) but
explained largely by the presence of primaquine.
Discussion
This is the first study documenting the presence of poor-quality
medicines in the health facility supply chain throughout PNG.
About half (48.3%) of all surveyed providers across the country
were found to stock medicines that failed chemical analysis of the
amount of API. This survey focused on antimalarial medicines and
two antibiotics as examples of other anti-infective drugs. In
conjunction with two earlier small-scale studies that detected
substandard, falsified and counterfeit amodiaquine, amoxicillin,
artemether and artesunate in samples collected from private
pharmacies in Port Moresby [29,37], this study confirms the
presence of poor-quality medicines in both the public and private
sectors in PNG.
While the majority of all medicine samples collected for this
study was of good quality, most primaquine tablet samples (78.4%)
failed the chemical content analysis. Most of the failed primaquine
samples contained less than 70% API (i.e. ,5.25 mg/tablet
instead of 7.5 mg) and three amodiaquine samples contained
between 41.6 and 51.3% API (i.e. 41.6–51.3 mg/tablet instead of
100 mg). At these levels, the drugs are unlikely to have a full
therapeutic effect, but may contribute to the development of
resistance of the parasites. On the other end of the spectrum, two
samples of quinine containing over 105% API may exacerbate
adverse effects in patients due to the drug’s narrow therapeutic
index [38].
Table 3. Acceptable ranges of active pharmaceutical ingredients and respective references.
Active ingredient Acceptable range (% active ingredient)* Reference
Amodiaquine 95.0–105.0 British Pharmacopoeia (BP)
Amoxicillin capsule 500 mg 92.5–110.0 British Pharmacopoeia (BP)
Amoxicillin tablet 250 mg 90.0–110.0 British Pharmacopoeia (BP)
Artemether 90.0–110.0 British Pharmacopoeia (BP)
Artesunate 90.0–110.0 International Pharmacopoeia (IP)
Chloroquine 92.5–107.5 British Pharmacopoeia (BP)
Doxycycline hyclate 100 mg 95.0–105.0 British Pharmacopoeia (BP)
Lumefantrine 90.0–110.0 British Pharmacopoeia (BP)
Primaquine 93.0–107.0 United States Pharmacopoeia (USP)
Pyrimethamine 90.0–110.0 British Pharmacopoeia (BP)
Quinine sulphate 95.0–105.0 British Pharmacopoeia (BP)
Sulphadoxine 90.0–110.0 British Pharmacopoeia (BP)
*Relative to labelled amount.
doi:10.1371/journal.pone.0096810.t003
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Primaquine plays a central role in the control of P. vivax malaria
and, more generally, in current efforts focussed on malaria
elimination [39]. Primaquine is the only drug currently available
for the elimination of P. vivax and P. ovale hypnozoites, for which a
14-day regimen is currently recommended [1,40]. Primaquine is
also active against gametocytes of P. falciparum, including those
persisting after treatment with ACT [41], for which purpose a
single dose is considered sufficient [1,42]. While there remains
certain controversy around the impact of primaquine on malaria
transmission [43], the drug is considered a potentially important
tool against artemisinin-resistant P. falciparum malaria [42,44].
Poor-quality primaquine, as identified in abundance in this study,
may compromise the global strategy to contain the spread of
artemisinin-resistant P. falciparum and efforts of eliminating P. vivax.
At the same time, under-dosing of primaquine may provide false
reassurance as to the incidence and severity of major drug-related
adverse effects such as haemolytic anaemia in G6PD deficient
patients, and methaemoglobinaemia [45,46]. The evidence of the
wide-spread availability of poor-quality primaquine found in this
study alongside results from investigations in other locations
[6,47,48] is therefore a concern for all countries in which
primaquine should have a major role in malaria control, including
settings in which the drug is already frequently used [48,49].
Drug quality needs to be considered alongside aspects of safety
in the discussion about the application of primaquine for reducing
P. falciparum malaria transmission and radical cure of P. vivax.
Broader confirmatory investigation into the quality of primaquine
is an urgent priority as part of the assessment of measures of
quality control and quality assurance in malaria control and
research programs that use primaquine.
The results presented in this study are limited to chemical
content analysis by HPLC and LC-MS and did not comprise
dissolution testing, which would have provided complementary
information related to the drugs’ bioavailability, particularly for
poorly aqueous-soluble drugs such as sulphadoxine-pyrimeth-
amine [50]. Disintegration and dissolution have been reported in
other studies as important indicators of poor drug quality
[47,51,52]. A more comprehensive quality assessment, as recom-
mended by the US Pharmacopoeia [50] and implemented in
Amazon countries [47], should be considered in subsequent
investigations. Systematic visual inspection of the packaging was
not included as some samples were repacked from large jars in
health facilities. Inspection of the packages might have helped to
classify the poor-quality samples. Classification as counterfeit
(intellectual property infringement) or falsified (both considered
deliberate actions), substandard (e.g. as a result of poor manufac-
turing practice) or degraded is important in order to identify
appropriate solutions [17]. Responses from manufacturers con-
firmed the authenticity of certain poor-quality products but
whether the low chemical content in the samples was a result of
poor manufacturing, negligence, or deliberate action cannot be
judged based on the available information. Poor-quality medicines
were ubiquitous in the health facility supply chain and as
commonly found in central warehouses and hospitals as in remote
aid posts that often lack appropriate storage facilities. This suggests
that poor-quality medicines identified in this study are unlikely to
be a result of inadequate transport and storage conditions, but
rather of poor manufacturing.
In the absence of any systematic sampling of medicines for
quality control [27] and only two previous small scale studies
[29,37], this survey including samples from across the country is
the most representative and comprehensive data on medicines
quality in PNG available to date. The inclusion of providers at all
levels of the supply chain adds extra value to the data and the overt
collection of medicines is unlikely to have introduced a major bias
under the assumption that the health facility officers-in-charge
were unaware of the quality of individual medicines on their
shelves. A collection of additional essential medicines could have
provided a more comprehensive picture of medicine quality in
PNG health facilities, but was beyond the scope of this study.
Nationwide surveys on medicine quality often focus on private
sector providers which are generally less well regulated and have
been found to sell poor-quality drugs [17,30,53]. The importance
of including the health facility sector in such studies is reflected in
our finding of poor-quality products, even though extending the
sampling of medicines to private sector providers across PNG
would be an important next step.
The wide-spread availability of poor-quality medicines in formal
health facilities reflects the lack of adequate quality control and
regulatory mechanisms in PNG [27]. As a consequence, any type
of poor-quality medicine, including fake artemisinin derivatives
that have in the past been found in southeast Asia [49,53], could in
the future easily enter and spread through the local medicines
market. The fact that only two sampled medicines (both
artemether-lumefantrine) were WHO prequalified products calls
into question the standards and procedures applied in the central
procurement of medicines. Poor-quality samples of primaquine
from one manufacturer (BDH Industries) were label ‘‘NVBDCP
[Indian National Vector Borne Disease Control Program]
SUPPLY, NOT FOR SALE’’ raising further questions about
drug supply channels (Figure S1).
In order to protect patients and safeguard the efficacy of
medicines, concerted global and local efforts are necessary [11,54].
Clinical practitioners and pharmacists in PNG should be aware
that the availability and inadvertent administration of poor-quality
medicines could result in an increase in morbidity or mortality due
Table 5. Origin of analysed and failed samples according to package labels.
Country Analysed samples Failed samples
N (%) N (%)
China 206 (57.2) 4 (10.8)
India 147 (40.8) 32 (86.5)
Indonesia 5 (1.4) 1 (2.7)
Switzerland 1 (0.3)
Unclear 1 (0.3)
Total 360 37
doi:10.1371/journal.pone.0096810.t005
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to malaria or sepsis. Given the difficulties in collecting valid
relevant aggregate data on drug quality and the likely delay in
analysing the results and promulgating the findings, the present
data suggest that individual PNG clinicians should include poor-
quality medicine as part of the differential diagnosis of repeated
unexpected treatment failure with a particular therapy, not only in
the case of malaria. We recommend that alternative formulations
are sourced and used in this situation, that samples of the suspect
treatment are retained for subsequent content analysis in a central
facility, and that these measures are communicated to the National
Department of Health so that wider action can be considered. At
the same time, urgent measures are required to stop the
availability of poor-quality products in both the public and the
private sector. First steps should include limiting procurement of
drugs to WHO prequalified products and implementing routine
quality testing. Basic low-tech test procedures can be used as a
cost-effective means to routinely screen medicines arriving in the
country and to test samples collected from peripheral facilities and
retailers, without requiring advanced technology [50,55]. Sophis-
ticated analyses based for example on HPLC, while unlikely to be
cost-effective and sustainable for high numbers of samples [10],
should be applied to validate the basic test results and provide
more in-depth information on poor-quality medicines [47,50].
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Figure S1 Photographs of packages containing poor-quality
medicines.
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Table S1 API content results for primaquine samples measured
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